Valvular & structural heart disease
ACURATE neo2 versus SAPIEN 3 Ultra (Ultra) for transcatheter aortic valve implantation
Main finding · Device successResult — go to the resultOdds ratio 1.961 95% CI 1.269–3.031Authors' conclusion
Short-term outcomes after TAVI using the Neo2 or Ultra THV were excellent and, overall, comparable. However, transvalvular gradients were lower with the Neo2, which translated into higher rates of device success. Rates of mild PVL were significantly lower with the Ultra THV.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI)
- Participants
- 1,356 patients472 matched pairs
- Exposure
- ACURATE neo2 vs SAPIEN 3 Ultra for TAVI
- Neo2 (Neo2)n = 608
- Ultran = 748reference
- Outcome
- Device success (latest VARC definitions)
Methodological details4 centres, propensity-score matched, inverse probability treatment weighting
- 4 centres
- Propensity-score matched
- Inverse probability treatment weighting
Main finding
Device success
Odds ratio
1.961
95% CI 1.269–3.031
P = 0.002
By group
Neo2vs Ultra
OR 1.961 (95% CI 1.269–3.031); P = 0.002
As reported in the abstract
Observational data: associations, not effects.
Further findings
Moderate to severe PVL · after PSM
P = 0.725
Elevated transvalvular gradients (≥20 mmHg) · after PSM
P < 0.001
Mild PVL
P < 0.001
Safety
Clinical events · 30 days
- Comparable between the 2 groups
Original publication
ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation. EuroIntervention. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →